ImmuPharma plc (LON:IMM – Get Free Report) shares rose 27.3% on Friday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.97 ($0.06). Approximately 13,061,318 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 21,589,580 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Trading Up 26.3 %
The firm has a market cap of £20.51 million, a P/E ratio of -492.40 and a beta of 1.53. The company’s 50-day moving average is GBX 2.39 and its two-hundred day moving average is GBX 1.93.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- How Investors Can Find the Best Cheap Dividend Stocks
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- How Can Investors Benefit From After-Hours Trading
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- What is the Nasdaq? Complete Overview with History
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
